OTIPRIO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OTIPRIO (OTIPRIO).
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to inhibition of DNA replication and transcription.
| Metabolism | Ciprofloxacin is metabolized in the liver via CYP1A2 and CYP3A4; however, systemic absorption following otic administration is minimal. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 80% over 24 hours) via glomerular filtration; biliary/fecal elimination accounts for <5%. |
| Half-life | Mean terminal elimination half-life is approximately 4.5 hours (range 3-6 hours); prolonged in renal impairment requiring dose adjustment. |
| Protein binding | Approximately 10% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid compartments. |
| Bioavailability | Otologic suspension: local application bypasses systemic absorption; negligible systemic bioavailability (<0.1%) due to minimal transmucosal absorption across the tympanic membrane and middle ear mucosa. |
| Onset of Action | Otologic suspension: clinical evidence of middle ear fluid clearance observed within 48-72 hours after a single application; tympanostomy tube placement allows direct middle ear delivery. |
| Duration of Action | Sustained therapeutic effect for up to 4-6 weeks after a single dose (0.1 mL instilled into ear canal); may require repeat administration if reinfection occurs. |
| Molecular Weight | 497.5 |
1 mg/kg intravenous infusion over 1 hour every 12 hours; typical adult dose is 100 mg every 12 hours.
| Dosage form | INJECTABLE, SUSPENSION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; for GFR 15-29 mL/min, reduce dose to 1 mg/kg every 24 hours; for GFR <15 mL/min or hemodialysis, 1 mg/kg every 48 hours. |
| Liver impairment | No adjustment for mild hepatic impairment (Child-Pugh A). For moderate to severe (Child-Pugh B or C), reduce dose to 0.5 mg/kg every 12 hours. |
| Pediatric use | 1 mg/kg intravenous infusion over 1 hour every 12 hours for children ≥2 years; maximum dose 100 mg per dose. |
| Geriatric use | No specific dose adjustment required; monitor renal function and consider age-related decline in GFR. |
| 1st trimester | No adequate studies in pregnant women; use only if potential benefit justifies potential risk to fetus. Animal studies show no teratogenicity at clinically relevant doses. |
| 2nd trimester | Same as T1; no evidence of harm but limited human data. |
| 3rd trimester | Same as T1; use with caution near term due to potential for hypotension in neonate if absorbed systemically. |
Clinical note
Comprehensive clinical and safety monograph for OTIPRIO (OTIPRIO).
| Placental transfer | Unlikely to cross placenta significantly due to local administration (intratympanic injection) and high molecular weight; no data on systemic absorption. |
| Breastfeeding | No data on presence in human milk; not likely to produce clinically relevant systemic exposure due to local administration. Use with caution, weighing benefit vs risk. |
■ FDA Black Box Warning
No black box warning applies to OTIPRIO (ciprofloxacin otic suspension).
| Serious Effects |
Hypersensitivity to ciprofloxacin or any quinoloneHypersensitivity to any component of formulation
| Precautions | Use only in intact tympanic membrane with tympanostomy tubes, Not for systemic infections, Risk of hypersensitivity reactions, Prolonged use may result in overgrowth of nonsusceptible organisms including fungi |
| Food/Dietary | No known food interactions. Avoid water entering the ear canal for 48 hours post-dose. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | OTIPRIO (ciprofloxacin otic suspension) is not absorbed systemically after topical otic administration. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical otic ciprofloxacin have not been conducted. However, systemic ciprofloxacin is known to cross the placenta and cause arthropathy in juvenile animals; therefore, use during pregnancy is recommended only if clearly needed. No specific fetal risks by trimester are established for topical otic use. |
| Fetal Monitoring | No specific monitoring is typically required beyond standard pregnancy care. However, if used during pregnancy, monitor for any signs of maternal hypersensitivity or local adverse reactions. Fetal monitoring is not indicated due to lack of systemic exposure. |
| Fertility Effects | No studies have been conducted on the effects of OTIPRIO on fertility. Systemic ciprofloxacin has not been associated with impaired fertility in animal studies. Given the minimal systemic absorption after otic administration, no effects on fertility are expected. |
| OTIPRIO (ciprofloxacin otic suspension) is indicated for acute otitis externa (swimmer's ear) and acute otitis media with tympanostomy tubes (AOMT). It is a fluoroquinolone antibiotic that requires a single-dose administration by a healthcare professional. After instillation, the patient should remain with the treated ear facing upward for 5-10 minutes to ensure adequate penetration. Avoid use in patients with known hypersensitivity to fluoroquinolones. Not for systemic use. |
| Patient Advice | This medication is given by your doctor in the office; you will not need to apply it yourself. · After the medicine is placed in your ear, lie still with the affected ear facing up for 5-10 minutes. · Do not get water in your ear for at least 48 hours after treatment. Use a cotton ball with petroleum jelly during showering. · Inform your doctor if you have ear discharge, ear tubes, or a perforated eardrum. · Contact your doctor if you experience worsening pain, itching, or new symptoms. |